Donna E. Hogge
YOU?
Author Swipe
View article: Supplementary Figures 1-4, Table 1 from Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers
Supplementary Figures 1-4, Table 1 from Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers Open
PDF file - 1.2MB
View article: Data from Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers
Data from Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers Open
Excessive signaling from the Wnt pathway is associated with numerous human cancers. Using a high throughput screen designed to detect inhibitors of Wnt/β-catenin signaling, we identified a series of acyl hydrazones that act downstream of t…
View article: Data from Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers
Data from Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers Open
Excessive signaling from the Wnt pathway is associated with numerous human cancers. Using a high throughput screen designed to detect inhibitors of Wnt/β-catenin signaling, we identified a series of acyl hydrazones that act downstream of t…
View article: Supplementary Figures 1-4, Table 1 from Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers
Supplementary Figures 1-4, Table 1 from Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers Open
PDF file - 1.2MB
View article: Data from An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers
Data from An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers Open
Many promising new cancer drugs proceed through preclinical testing and early-phase trials only to fail in late-stage clinical testing. Thus, improved models that better predict survival outcomes and enable the development of biomarkers ar…
View article: Supplemental Material from An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers
Supplemental Material from An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers Open
Supplemental Methods Supplemental Table 1 Supplemental Figures 1-6 1. Pretreatment with cytarabine potentiates the effects of FED in AML xenografts. Supplemental Figure 2. PF cytometry analysis of AML samples. Supplemental Figure 3. Immuno…
View article: Data from An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers
Data from An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers Open
Many promising new cancer drugs proceed through preclinical testing and early-phase trials only to fail in late-stage clinical testing. Thus, improved models that better predict survival outcomes and enable the development of biomarkers ar…
View article: Supplemental Material from An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers
Supplemental Material from An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers Open
Supplemental Methods Supplemental Table 1 Supplemental Figures 1-6 1. Pretreatment with cytarabine potentiates the effects of FED in AML xenografts. Supplemental Figure 2. PF cytometry analysis of AML samples. Supplemental Figure 3. Immuno…
View article: Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses Open
CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine in a synergistic 1:5 molar ratio, is approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplas…
View article: Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada Open
Understanding how patient‐reported quality of life (QoL) and socioeconomic status (SES) relate to survival of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) may improve prognostic information sharing. This study explores a…
View article: Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis Open
IntroductionThe WHO 2016 AML-MRC designation applies to AML patients (pts) with a history of myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm, a MDS-related cytogenetic abnormality, or multilineage dysplasia in >50% of ≥2 …
View article: Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia Open
CPX-351 is a dual-drug liposomal encapsulation of cytarabine/daunorubicin. In a phase 3 study (ClinicalTrials.gov Identifier: NCT01696084), patients aged 60-75 years with newly diagnosed, high-risk/secondary AML received 1-2 induction cycl…
View article: The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML)
The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML) Open
IntroductionCPX-351 (Vyxeos®), a dual-drug liposomal encapsulation of cytarabine (C) and daunorubicin (D) at a synergistic ratio, is approved by the FDA and EMA for adults with newly diagnosed therapy-related AML or AML with myelodysplasia…
View article: CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia Open
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a s…
View article: Excellent real‐world outcomes of adults with Burkitt lymphoma treated with <scp>CODOX</scp>‐M/<scp>IVAC</scp> plus or minus rituximab
Excellent real‐world outcomes of adults with Burkitt lymphoma treated with <span>CODOX</span>‐M/<span>IVAC</span> plus or minus rituximab Open
Summary Treatment of Burkitt lymphoma ( BL ) with intensive, multi‐agent chemotherapy with aggressive central nervous system ( CNS ) prophylaxis results in high cure rates, although no regimen is standard of care. We examined population‐ba…
View article: Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience
Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience Open
The natural history of patients with myelodysplastic syndromes (MDS) is variable. The Revised International Prognostic Score (IPSS-R) is commonly used in practice to predict outcomes in patients with MDS at both diagnosis and before hemato…
View article: Outpatient Autologous Stem Cell Transplants for Multiple Myeloma—Analysis of Safety and Outcomes in a Tertiary Care Centre
Outpatient Autologous Stem Cell Transplants for Multiple Myeloma—Analysis of Safety and Outcomes in a Tertiary Care Centre Open
Background: High dose chemotherapy and autologous stem cell transplant (ASCT) is the preferred consolidation strategy in the treatment of eligible patients with multiple myeloma and related plasma cell dyscrasias. Given the high volume of …
View article: Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial Open
Introduction: CPX-351 is a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio. A recent phase III trial showed superior survival with CPX-351 versus standard 7 + 3 cytarabine-daunorubicin induction in secondary acute…
View article: Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia
Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia Open
Summary Acute Myeloid Leukaemia ( AML ) is a rare but serious group of diseases that require critical decision‐making for curative treatment. Over the past decade, scientific discovery has revealed dozens of prognostic gene mutations for A…
View article: Pre-Transplant Vitamin D Deficiency is Associated with Inferior Overall Survival but not Associated with Relapse Free Survival or Cumulative Incidence of GVHD Post Adult Hematopoietic Cell Transplantation for Hematological Malignancies
Pre-Transplant Vitamin D Deficiency is Associated with Inferior Overall Survival but not Associated with Relapse Free Survival or Cumulative Incidence of GVHD Post Adult Hematopoietic Cell Transplantation for Hematological Malignancies Open
Vitamin D is known to have immuno-modulatory properties in autoimmunity and transplantation. Few previous retrospective studies in pediatric and adult hematopoietic cell transplantation (HCT) have shown variable association of pre-transpla…
View article: Dosing Chemotherapy in Obese Adult Acute Myelogenous Leukemia Patients: A Comparison of Actual Body Weight Versus Adjusted Body Weight
Dosing Chemotherapy in Obese Adult Acute Myelogenous Leukemia Patients: A Comparison of Actual Body Weight Versus Adjusted Body Weight Open
The prevalence of obesity has increased over the last few decades. The effect of obesity in the field of malignant hematology is poorly understood. ASCO published guidelines recommending actual body weight (ABW) based dosing of obese patie…
View article: An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers
An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers Open
Many promising new cancer drugs proceed through preclinical testing and early-phase trials only to fail in late-stage clinical testing. Thus, improved models that better predict survival outcomes and enable the development of biomarkers ar…